X4 Pharmaceuticals Presents Mavorixafor Phase 3 Trial Plans for Primary Chronic Neutropenia
Bitget2026/10/29 14:04- X4 Pharmaceuticals outlined plans at its virtual investor day to fully enroll 126 patients in the Phase 3 4WARD trial by Q4 2026.
- Topline 4WARD data for mavorixafor in primary chronic neutropenia are expected in Q1 2028.
- Potential U.S. FDA approval for that indication is targeted for late 2028 or early 2029.
- The Phase 2b 4STEPS trial, evaluating G-CSF dose reduction with mavorixafor, targets its first patient visit in Q1 2027.
- Topline 4STEPS data are expected in the first half of 2028; planned enrollment is approximately 25 patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Crypto prices
More
